Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma OTC - A step beyond Generic Drugs - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jan 8, 2013

    Pharma OTC - A step beyond Generic Drugs

    As patents expire and generic drugs becoming available, pharma companies are looking forward to penetrate in the Over the Counter (OTC) market. As per the USFDA website, OTC drugs are defined as "drugs that are safe and effective for use by the general public without seeking treatment by a health professional". This means an OTC drug will not require prescription to buy and can be bought as any other consumer products.

    OTC drugs are mainly available for commonly occurring conditions like common cold, tobacco smoking dependence, dental care, allergies, heartburn, obesity, dermatitis etc. There are more than 80 therapeutic categories of OTC drugs available for categories like acne to weight control products.

    Why OTC drugs?

    For Governments - The rising budgets for healthcare are forcing governments to find ways to control the costs. As per IMS, - Every dollar spent, by consumers on OTC medicines saves US$ 6-7 for US healthcare. The OTC medicines provide value through significantly expanded access to treatment for the most frequent and common illness.

    For Patients - As these medicines help to save time of making Physician visits, even patients tend to opt for OTC medicines.

    For Companies - Both innovator and generic companies have reasons to promote the OTC drugs. The innovator companies introduce the OTC drug, to extend the life of their product which is nearing patent expiry or has already witnessed high competition. On the other hand, the generic companies too enter the market depending on the various circumstances; one of the biggest reasons being, the acceptability of generic drugs decreases when the OTC version is available.

    Which Companies Are Present?

    The company's task remains undone, if the OTC drug is not marketed properly. While pharma companies have to prove to the drug regulators that the said drug fits for the OTC segment and the company has fulfilled all the requirements. The companies also have to go for aggressive marketing in order to reach the customers. Various acquisitions have taken place in order to tap this segment.

    Global drug companies like Johnson and Johnson, Sanofi, Pfizer, GSK focus on OTC segment. In light of the same, Sanofi has been making various acquisitions viz Kernpharm in the Netherlands, Laboratories Gramon in Argentina, Oenobiol in France, BMP Sunstone in China and Chattem in the United States.

    On the other hand there are companies like Perrigo, which derive large part of its revenues from the sale of OTC drugs.

    Among the Indian players, Dr Reddy's generates approx US$ 100 m of revenues from the sales of OTC drugs in various geographies; largely from Russia and US. Sun Pharma's subsidiary Taro too is present in OTC segment for dermatology products. The other players being Ranbaxy, Wockhardt, and Cadista (Subsidiary of Jubilant Lifescience). These generate some part of their revenues from OTC drugs like Cetrizine.

    It is pertinent to note that the Indian companies are not very active in the OTC market as compared to various global generic companies, like Perrigo. Thus, the Indian companies will have to compete with not only the Innovator companies but also companies like Perrigo in order to penetrate in this segment.

    Perrigo - A classic example of OTC focused company

    Perrigo a US based company, is one of the strong players in the OTC market. Perrigo expects future opportunity of ~ US$ 41.7 bn opportunity for OTC market

    Standalone financial snapshot
    Potential Switch - Products/Categories Brand Sales (US$ Billion)
    Statins 17
    Singulair 4.8
    Prostate 3.6
    Cox- 2 Inhibitors 3.5
    Erectile Dysfunction 2.9
    Nasal Allergy 2.5
    Overactive Bladder 2.2
    Migraine 1.7
    Omega-3 Fish Oils 1.6
    Opthalmic- Allergy/Dry Eye 1.3
    Acne 0.6
    Total 41.7
    Source: Perrigo Presentation

    Perrigo has laid down future pipeline of multi-billion drugs of ~US$ 17.4 bn to bring under OTC segment. The company is targeting drugs like Nexium, Protonix, Prevacid etc. Further, even Pfizer is targeting to make OTC version of Lipitor brand.

    Indian companies are either selling these drugs or hold exclusivity, thus OTC version will impede the generic sales of Indian companies.

    To conclude

    Global pharma companies are making huge acquisitions and pushing the OTC brands. Innovators are making higher expenditures on advertisements and sales force to promote their brands. This is bound to hamper the sales of the generics given the OTC version of the same drug is available. On the other hand in some countries like Russia, the government is pushing OTC drugs. Eventually, these events will prove to be added challenges for the generic companies especially, pure generic players.

    While generic companies too have entered this segment they have to compete with the parent companies' brand. It should be noted that, in the OTC segment the consumers tend to opt for the innovator's brand than generic company's brand at a given price differential.

    Thus the OTC model will tend to be successful for those companies which are active to market their drugs. As most of the Indian companies are pure generic companies, very few companies will be able to penetrate well in the OTC market.

      Bhavita Nagrani (Research Analyst) is a Chartered Financial Analyst (ICFAI) with nearly six years of experience in the field of equity research. She has a deep understanding of the global as well as the domestic Healthcare industry and keenly tracks the developments therein. When it comes to stock investing, she is a strong advocate of the bottom-up approach to stock picking and has a remarkable ability to discern nuances in the business models of companies belonging to the same industry. Bhavita is the contributor to our large cap franchise, StockSelect.



    Equitymaster requests your view! Post a comment on "Pharma OTC - A step beyond Generic Drugs". Click here!

    1 Responses to "Pharma OTC - A step beyond Generic Drugs"

    ramanlal karwa

    Jan 15, 2013

    In my openion as a qualified pharmacist,in indian scenario where patient depends more on doctor's prescription,it is advisable to promote the concept of generic drugts at a low cost by cutting expenses on promotion of branded otc products.Considering this aspect in my openion futuire is bright for generic drugs as compare to otc products.

    Equitymaster requests your view! Post a comment on "Pharma OTC - A step beyond Generic Drugs". Click here!

    More Views on News

    Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

    May 29, 2017

    Currency fluctuation and one time provision impacts operating margins.

    Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

    May 18, 2017

    Base price erosion in the US and lower Zetia sales impacts profits.

    Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

    Mar 11, 2017

    Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

    Laurus Labs Ltd (IPO)

    Dec 6, 2016

    Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    More Views on News

    Most Popular

    Of "Shaky" Demonetisation Statistics, Arun Jaitley and Black Money(Vivek Kaul's Diary)

    May 22, 2017

    When it comes to identifying black money, 2016-2017 has been a fairly average year for the income tax department, demonetisation notwithstanding.

    Just Like Before, the Market is about to Crash(Outside View)

    May 17, 2017

    Markets are at record highs. Fear is at record lows. How does this end? When does this end?

    Why We Skipped This 70% Gainer(The 5 Minute Wrapup)

    May 18, 2017

    Underreporting of bad loans by some private sector banks casts a cloud over the sector's clean image so far.

    Double Your Money with Derivatives(Daily Profit Hunter)

    May 19, 2017

    Asad Dossani discusses how you can double your money with derivatives.

    The Rise and Fall of Shilpi Cable Technologies(Chart Of The Day)

    May 19, 2017

    How Shilpi Cable lost over 70% of its market cap in one month.

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-6143 4055. Fax: +91-22-2202 8550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407


    May 30, 2017 10:58 AM